ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable.
Thomas H BrannaganMichaela Auer-GrumbachJohn L BerkChiara BrianiVera BrilTeresa CoelhoThibaud DamyAngela DispenzieriBrian M DrachmanNowell FineHanna K GagginMorie GertzJulian D GillmoreEsther GonzalezMazen HannaDavid R HurwitzSami L KhellaMathew S MaurerJose Nativi-NicolauKemi OlugemoLuis F QuintanaAndrew M RosenHartmut H SchmidtJacqueline ShehataMarcia Waddington-CruzCarol WhelanFrederick L RubergPublished in: Orphanet journal of rare diseases (2021)
Patients with ATTR amyloidosis are suspected to have a higher risk of morbidity and mortality due to age and underlying ATTR amyloidosis-related organ dysfunction. While further research is needed to characterize this risk and management implications, ATTR amyloidosis patients might require specialized management if they develop COVID-19. The risks of delaying diagnosis or interrupting treatment for patients with ATTR amyloidosis should be balanced with the risk of exposure in the health care setting. Both physicians and patients must adapt to a new construct for care during and possibly after the pandemic to ensure optimal health for patients with ATTR amyloidosis, minimizing treatment interruptions.
Keyphrases
- healthcare
- end stage renal disease
- multiple myeloma
- coronavirus disease
- ejection fraction
- chronic kidney disease
- sars cov
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- primary care
- palliative care
- oxidative stress
- pulmonary embolism
- combination therapy
- social media
- pain management
- chronic pain
- replacement therapy